Biomerica Inc (BMRA) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
In fiscal 2026, Biomerica reported revenue of $4.5M, down 16.2% from $5.3M the year before. Net income was -$3.8M (a -84.8% net margin), or -$1.30 per diluted share. Gross margin was 8.1% and operating margin was -119.5%. Operating activities generated -$3.4M of cash. At fiscal year end, Biomerica held $6.8M in total assets against $4.1M in total liabilities, including $1.3M of cash and equivalents.
Open the full interactive Biomerica financials → Quarterly statements, key ratios, valuation history and price charts.
Biomerica Key Stats
| Share Price | $1.85 |
|---|---|
| Market Cap | $5.4M |
| Revenue YoY Growth | -16.2% |
| 52-Week Range | $1.49 – $3.20 |
| Shares Outstanding | 2.9 million (basic, 2026 Q4) |
Biomerica Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $7.2M | $18.9M | $5.3M | $5.4M | $5.3M | $4.5M |
| Gross Profit | $496,981 | $3.0M | $446,000 | $611,000 | $498,000 | $362,000 |
| Operating Income | -$6.5M | -$4.5M | -$7.2M | -$6.4M | -$5.1M | -$5.3M |
| Pre-Tax Income | -$6.5M | -$4.5M | -$7.1M | -$5.9M | -$5.0M | -$3.8M |
| Income Tax | $13,057 | $23,719 | $51,000 | $42,000 | $1,000 | $23,000 |
| Net Income | -$6.5M | -$4.5M | -$7.1M | -$6.0M | -$5.0M | -$3.8M |
| Diluted EPS | -$4.32 | -$2.88 | -$4.00 | -$2.88 | -$2.16 | -$1.30 |
Biomerica Quarterly Results
| 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 | |
|---|---|---|---|---|
| Revenue | $1.4M | $1.2M | $987,000 | $876,000 |
| Net Income | $2,000 | -$1.3M | -$1.3M | -$1.1M |
| Diluted EPS | — | -$0.45 | -$0.44 | -$0.39 |
Biomerica Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.2M | $5.9M | $9.7M | $4.2M | $2.4M | $1.3M |
| Current Assets | $9.2M | $9.4M | $12.8M | $7.7M | $4.9M | $4.0M |
| Total Assets | $11.8M | $11.4M | $14.5M | $9.3M | $5.9M | $6.8M |
| Current Liabilities | $1.3M | $2.0M | $1.9M | $2.2M | $1.7M | $2.5M |
| Total Liabilities | $2.6M | $3.0M | $2.7M | $2.7M | $1.8M | $4.1M |
| Shareholders' Equity | $9.2M | $8.3M | $11.7M | $6.6M | $4.1M | $2.6M |
Biomerica Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$5.3M | -$480,532 | -$5.5M | -$5.4M | -$3.8M | -$3.4M |
| Cash From Investing | -$295,583 | -$170,336 | -$78,000 | -$115,000 | -$37,000 | -$1,000 |
| Cash From Financing | $1.1M | $2.4M | $9.4M | -$81,000 | $2.1M | $2.3M |
| Free Cash Flow | -$5.4M | -$537,432 | -$5.5M | -$5.4M | -$3.9M | — |
Figures from Biomerica's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Biomerica financials page for every line item.
Biomerica Company Profile
| Ticker | BMRA |
|---|---|
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | Irvine, California |
| Incorporated in | Delaware |
| Fiscal Year End | May 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000073290 |
Frequently Asked Questions
What was Biomerica's revenue in fiscal 2026?
Biomerica (BMRA) reported revenue of $4.5M for fiscal 2026.
What is Biomerica's annual revenue history?
Biomerica's annual revenue by fiscal year: 2021: $7.2M; 2022: $18.9M; 2023: $5.3M; 2024: $5.4M; 2025: $5.3M; 2026: $4.5M.
What was Biomerica's net income in fiscal 2026?
Biomerica reported net income of -$3.8M for fiscal 2026.
What was Biomerica's earnings per share (EPS) in fiscal 2026?
Biomerica's diluted EPS was -$1.30 for fiscal 2026 (adjusted for any later stock splits).
What was Biomerica's revenue last quarter?
In its most recent reported quarter (2026 Q4), Biomerica reported revenue of $876,000.
How many shares of Biomerica are outstanding?
Biomerica reported a weighted average of 2.9 million basic shares outstanding in 2026 Q4.
What is Biomerica's market cap?
Based on its latest closing price, Biomerica (BMRA) has a market capitalization of about $5.4M.
When does Biomerica's fiscal year end?
Biomerica's fiscal year end, as registered with the SEC, is May 31.
Where is Biomerica headquartered?
Biomerica lists its business address in Irvine, California in its SEC filings.
Biomerica Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →